Freeze-drying process of tilpotide for injection
Through freeze-drying technology and reasonable lyophilization process parameter control, lyophilized tielpopeptide powder for injection was prepared, which solved the problem of insufficient stability and transportation convenience of tielpopeptide preparations, and achieved higher drug stability and the improvement of storage conditions.
Patent Information
- Application Number
- CN202411362806.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-27
- Publication Date
- 2024-11-15
AI Technical Summary
The existing terpopeptide preparations are mainly in the form of aqueous solvents, which have problems with insufficient stability and transportation convenience, and lack research and application of lyophilized dosage forms.
Using freeze-drying technology, by accurately controlling the lyophilized process parameters and selecting appropriate excipients, lyophilized tielpo peptide lyophilized powder for injection is prepared, which improves the stability and storage conditions of the drug, reduces transportation and storage costs, and Simplified the redissolution process.
The stability of freeze-dried powder is significantly improved, and the storage conditions are increased from 4℃ to room temperature, the content is reduced and the growth rate of impurities is slowed down, and the rehydration performance is good, which reduces drug loss and extends the shelf life.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a freeze-drying process of telpotide for injection. Background Art
[0002] According to the diabetes etiology classification system proposed by the World Health Organization (WHO) in 1999, diabetes is scientifically divided into four main types: type 1 diabetes, type 2 diabetes, special types of diabetes and gestational diabetes. Among them, type 1 diabetes, type 2 diabetes and gestational diabetes are the most common types in clinical practice. For type 1 diabetes, although its etiology and pathogenesis have not been fully elucidated, it has been confirmed that its significant pathological and pathophysiological characteristics are a significant reduction or disappearance of the number of pancreatic β cells, which in turn leads to a significant decrease or complete loss of insulin secretion. As for type 2 diabetes, its etiology and pathogenesis have not yet been clarified, but it has been confirmed that its significant pathophysiological characteristics are a decrease in the ability of insulin to regulate glucose metabolism, that is, insulin resistance, accompanied by a decrease or relative decrease in insulin secretion due to defects in pancreatic β cell function. Special types of diabetes are types of diabetes with relatively clear etiology.
[0003] Tirzepatide is the first and only agonist of its kind that can activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, integrating the effects of two incretins into one molecule. GIP is an incretin that can complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to reduce food intake and increase energy expenditure, thereby reducing weight. When combined with GLP-1 receptor agonists, it may have a greater effect on metabolic disorders such as body weight, blood sugar and blood lipids. It is a 39-amino acid modified peptide based on the GIP sequence, containing 2 non-coding amino acids (aminoisobutyric acid, Aib), a C-terminal amide and a Lys residue at position 20, connected to 1,20-eicosanedioic acid through a linker. It can be used as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes, but is not suitable for type 1 diabetes.
[0004] Currently, there is only one dosage form of telpotide on the market, which is the telpotide injection originally developed by Eli Lilly. Its preparation is packaged in the form of a solution in a prefilled syringe and is administered with an automatic injection pen.
[0005] Eli Lilly's telpotide injection is a prefilled needle, and the prescription uses sodium chloride as an osmotic pressure regulator, disodium hydrogen phosphate heptahydrate as a pH buffer, hydrochloric acid and sodium hydroxide as pH regulators, and phenol as an antibacterial agent. The storage condition is 2~8℃, and the shelf life is 2 years.
[0006] Currently, there are no patents or literature regarding the lyophilized dosage form of telportopide, whether in terms of prescription or process.
[0007] At present, freeze-drying technology has been used as one of the important means to prepare stable drugs and biological products, showing broad development prospects. This technology can significantly improve the stability of drugs such as proteins, peptides, antibiotics, vaccines and liposomes, while greatly enhancing the convenience of transportation. This technology is particularly suitable for handling many heat-sensitive substances, such as proteins, peptides and microorganisms, and can effectively prevent them from denaturing or losing their biological activity during the processing process. In the process of drug production, freeze-drying technology can efficiently dry drugs under low temperature conditions. Through this process, the moisture in the drug can be removed to 95%~99%, thereby greatly reducing the risk of chemical degradation of the finished product and significantly improving the stability and quality of the drug.
[0008] Compared with traditional water-soluble drugs, freeze-dried powder drugs prepared by freeze-drying technology have the following significant advantages: 1) The enzymatic effect is weakened, and the original chemical and physiological properties are more stable, ensuring the quality and efficacy of the drug; 2) It can be quickly reconstituted after adding water, which greatly facilitates long-distance transportation and long-term storage, and effectively reduces drug loss; 3) It slows down the reduction of active substance content, extends the shelf life, and significantly improves the commercial value of the drug; 4) In the aqueous solution stage before the drug is dried, it can be accurately quantified by the filling machine, which improves production efficiency; 5) It can be sterilized directly by filtration, avoiding the selection of more complex terminal sterilization, such as moist heat sterilization or irradiation sterilization, for some aqueous solution preparations based on the guidance of the sterilization decision tree.
[0009] Freeze drying technology and its application in the pharmaceutical field, especially focusing on improving the chemical and physical stability of freeze-dried products by optimizing freeze drying process parameters and adding appropriate excipients. Although freeze drying is widely recognized for its mild and friendly characteristics, in practice, due to its complex process design, various seemingly minor problems will still occur in the finished preparations, thus affecting the stability of the product. Summary of the invention
[0010] In view of this, the present invention provides a freeze-drying process for telpotide for injection, improves the dosage form of telpotide preparations, innovatively applies freeze-drying technology, successfully prepares it into a freeze-dried powder form, and significantly improves the stability of telpotide drugs. Specifically, the quality of the product under storage conditions of 25°C is equivalent to or better than that of the pre-filled needle, while reducing the cost of transportation and storage; the rate of content reduction is significantly slower than that of the pre-filled needle; the rate of increase of total impurities (related substances) is significantly slower than that of the pre-filled needle. The freeze-dried powder injection does not need to be matched with an automatic injection pen, and can be reconstituted by drawing water for injection using an ordinary disposable syringe, which can save costs.
[0011] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0012] The present invention provides a stable lyophilized powder of telportopeptide for injection, comprising a polypeptide raw material drug, an excipient, an osmotic pressure regulator, a pH regulator and a solvent.
[0013] In some specific embodiments of the present invention, the content of the osmotic pressure regulator in the above-mentioned telpotide lyophilized powder for injection is 0.2-2%; the content of the lyophilized excipient is 0.5-10%; and the content of the pH regulator is 0.0001%-0.5%.
[0014] In some specific embodiments of the present invention, the osmotic pressure regulator of the above-mentioned lyophilized powder of telpotide for injection includes at least one of sodium chloride, phosphate, citrate, glycerol, propylene glycol, mannitol, sorbitol, glucose, fructose, lactose, trehalose, and sucrose.
[0015] In some specific embodiments of the present invention, the excipients of the above-mentioned telportopide lyophilized powder for injection include at least one of mannitol, sucrose, sorbitol, glucose, fructose, lactose, trehalose, dextran, cyclodextrin and cyclodextrin derivatives, chitosan and its derivatives, maltodextrin, amino acids, casein, and bovine serum albumin.
[0016] In some specific embodiments of the present invention, the pH adjuster of the above-mentioned telpotide lyophilized powder for injection includes at least one of citric acid and citrates, acetic acid and acetates, phosphoric acid and phosphates, sodium hydroxide, hydrochloric acid, lactic acid, and maleic acid.
[0017] In some specific embodiments of the present invention, the solvent of the above-mentioned telpotide lyophilized powder for injection is water for injection or physiological saline.
[0018] In some specific embodiments of the present invention, the above-mentioned telportopide lyophilized powder for injection also includes a solubilizer or a stabilizer, the content of which is 0.001-10%, and is composed of at least one of ethanol, propylene glycol, glycerol, polyethylene glycol, Kolliphor HS15, Kolliphor ELP, Tween 80, Tween 20, poloxamer 188, hydroxypropyl beta-cyclodextrin, and dodecylphosphocholine (DPC).
[0019] The present invention also provides a freeze-drying process for tepote for injection, comprising the following steps:
[0020] Step (1): mixing an excipient, 0.41 parts by weight of sodium chloride, 0.07 parts by weight of disodium hydrogen phosphate heptahydrate with water, dissolving them, and then mixing with 0.25 to 1.5 parts of telportion, dissolving them, adjusting the pH to 6, 6.5, 7, 7.5, 8, 8.5 or 9, filtering, and obtaining a lyophilized solution;
[0021] Step (2): freeze-drying the lyophilized solution to obtain a lyophilized preparation of tepoxetine for injection;
[0022] The freeze-drying comprises three stages: pre-freezing, primary drying and secondary drying;
[0023] The pre-freezing may or may not include an annealing step;
[0024] The pre-freezing conditions are: -40°C to -8°C, 3 to 7 hours;
[0025] The annealing conditions are: -15°C to -8°C, 2 hours;
[0026] The primary drying conditions are: 200 μbar, -20°C to -10°C, 20 hours;
[0027] The secondary drying conditions are: extreme vacuum, 10° C. to 20° C., and 8 to 10 hours.
[0028] In some specific embodiments of the present invention, the weight portion of the excipient in the above-mentioned freeze-drying process is 3 to 8 parts, and the component is at least one of mannitol, lactose, trehalose, and sucrose.
[0029] In some specific embodiments of the present invention, in the above freeze-drying process, the excipient is 3 to 8 parts of mannitol by weight.
[0030] In some specific embodiments of the present invention, in the above freeze-drying process, the excipient is 5 parts of lactose by weight.
[0031] In some specific embodiments of the present invention, in the above freeze-drying process, the excipient is 5 parts of trehalose by weight.
[0032] In some specific embodiments of the present invention, in the above freeze-drying process, the excipient is 5 parts of sucrose by weight.
[0033] In some specific embodiments of the present invention, in the above freeze-drying process, the excipients are 4 parts of trehalose and 1 part of mannitol, based on weight.
[0034] In some specific embodiments of the present invention, in the above freeze-drying process, the excipients are 3 parts of sucrose and 2 parts of mannitol, by weight.
[0035] In some specific embodiments of the present invention, the freeze-drying conditions of the above freeze-drying process are:
[0036] Pre-freezing: -40℃, 3 hours;
[0037] Primary drying: 200 μbar, -20°C, 20 hours;
[0038] Secondary drying: extreme vacuum, 20°C, 10 hours.
[0039] In some specific embodiments of the present invention, the freeze-drying conditions of the above freeze-drying process are:
[0040] Pre-freezing: -40℃, 3 hours;
[0041] Primary drying: 200 μbar, -20°C, 10 hours, then -10°C, 10 hours;
[0042] Secondary drying: extreme vacuum, 20°C, 5 hours, then 40°C, 3 hours.
[0043] In some specific embodiments of the present invention, the freeze-drying conditions of the above freeze-drying process are:
[0044] Pre-freezing: -40℃, 3 hours, then annealing at -15℃ for 2 hours, then -40℃, 2 hours;
[0045] Primary drying: 200 μbar, -20°C, 10 hours, then -10°C, 10 hours;
[0046] Secondary drying: extreme vacuum, 20°C, 5 hours, then 40°C, 3 hours.
[0047] In some specific embodiments of the present invention, the freeze-drying conditions of the above freeze-drying process are:
[0048] Pre-freezing: -40℃, 3 hours, then annealing at -8℃ for 2 hours, then -40℃, 2 hours;
[0049] Primary drying: 200 μbar, -20°C, 10 hours, then -10°C, 10 hours;
[0050] Secondary drying: extreme vacuum, 20°C, 5 hours, then 40°C, 3 hours.
[0051] The present invention also provides a lyophilized preparation of telpotide for injection prepared by the lyophilization process.
[0052] In some specific embodiments of the present invention, the above-mentioned lyophilized preparation of tilpotide for injection is composed of excipients, 0.41 parts of sodium chloride, 0.07 parts of disodium hydrogen phosphate heptahydrate, and 0.25-1.5 parts of tilpotide in parts by weight;
[0053] The weight portion of the excipient is 3 to 8 parts, and the component is at least one of mannitol, lactose, trehalose and sucrose.
[0054] In some specific embodiments of the present invention, the excipient in the above-mentioned lyophilized preparation of telpotide for injection is 3 to 8 parts of mannitol by weight.
[0055] In some specific embodiments of the present invention, the excipient in the above-mentioned lyophilized preparation of telpotide for injection is 5 parts of lactose by weight.
[0056] In some specific embodiments of the present invention, the excipient in the above-mentioned lyophilized preparation of telpotide for injection is 5 parts of trehalose by weight.
[0057] In some specific embodiments of the present invention, the excipient in the above-mentioned lyophilized preparation of telpotide for injection is 5 parts of sucrose by weight.
[0058] In some specific embodiments of the present invention, in the above-mentioned lyophilized preparation of telpotide for injection, the excipients are 4 parts of trehalose and 1 part of mannitol, based on weight.
[0059] In some specific embodiments of the present invention, the excipients of the above-mentioned lyophilized preparation of telpotide for injection are 3 parts of sucrose and 2 parts of mannitol, by weight.
[0060] The present invention firstly ensures that the freeze-drying process is carried out under optimal conditions by precisely controlling the freeze-drying process parameters, including the temperature and heating and cooling rates at each stage, the front box pressure, the holding time and the annealing. Secondly, the importance of the selection of excipients is emphasized. By rationally matching and using excipients, the generation of stress in the preparation can be effectively reduced and the stability of the product can be improved.
[0061] The practical results show that the lyophilized powder of telpotide prepared by the freeze-drying process optimized by the present invention has higher stability than the aqueous solution preparation, which is mainly reflected in the slower growth of total impurities, slower decrease of content, the long-term storage temperature is increased from 4°C to room temperature, and good rehydration performance. These advantages provide strong support for the research and development, production and storage of drugs. DETAILED DESCRIPTION
[0062] The present invention discloses a freeze-drying process for telportopide for injection. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0063] Since the quality of the final products of preparations obtained using different excipients and freeze-drying processes varies greatly, suitable excipients and freeze-drying processes are particularly important.
[0064] The freeze-drying formula design is the foundation and the first step to ensure stability. When selecting raw materials and excipients, it is necessary to fully study and select freeze-drying protective agents with higher eutectic points to facilitate the smooth progress of the sublimation stage and shorten the freeze-drying time. At the same time, the selection of suitable antioxidants and acid-base regulators is also the key to ensure the stability of the product. The total amount of solid matter in the formula also needs to be controlled within an appropriate range to avoid product rupture due to too low a substance content or too high a substance content that hinders the flow of water vapor during the drying process.
[0065] In the freeze-drying process, it is crucial to control temperature and pressure. The freeze dryer ensures that the freezing process of the drug solution can achieve the desired effect by accurately controlling the plate temperature. In the sublimation stage, the temperature and pressure also need to be accurately controlled to avoid excessive moisture remaining in the drug, which affects the quality.
[0066] In addition, annealing is an important step to enhance the stability of telpotide lyophilized preparations. Annealing can be performed during pre-freezing and at the end of lyophilization to reduce the mechanical stress and solute effect inside the product, thereby preventing problems such as denaturation or stress release during the later storage of the product. The annealing temperature should be lower than the eutectic point, which can increase product stability and improve the sublimation efficiency of the product.
[0067] On the other hand, annealing after freezing can also reduce the surface fraction of immunoglobulins, thereby maintaining the stability of the protein during storage; adding Tween 80, trehalose or polysorbate as a protective agent can reduce the formation of particles. The present invention successfully avoids the risk of drug degradation caused by incompatible substances by accurately selecting and using appropriate lyophilization excipients, and provides a safer and more effective solution for the application of freeze-drying technology.
[0068] The present invention provides a prescription and a freeze-drying process for preparing telpotide for injection.
[0069] First, the prescription is screened. In the freeze-drying process, in order to ensure that the product can maintain a stable cake-like solid appearance, suitable excipients need to be added. Generally speaking, excipients suitable for freeze-drying include carbohydrates, proteins, polymers, lipids, cellulose, amino acids, polyols and inorganic salt excipients. It should be noted that if there are substances incompatible with the active ingredients of the drug in the excipients, even if the moisture content of the product has been reduced to an extremely low level, it may still trigger unpredictable degradation reactions of the drug, such as oxidation reactions, reduction reactions, etc. Therefore, when selecting and using freeze-dried excipients, they must be strictly screened to ensure that they are compatible with telportin to ensure the quality and stability of the product. In the research and application of protein preparations, surfactants are widely used as protein stabilizers due to their unique properties. Common surfactants include polysorbates, Pluoronics, alkyl sugars and amino acid derivatives, which not only have the ability to stabilize proteins, but also can act as diluents to effectively reduce the aggregation caused by protein and peptide reconstruction. Its mechanism of action is to reduce protein aggregation by reducing the self-association and weak interaction forces between proteins. In addition to surfactants, sugars are also an important type of protein stabilizer. Taking trehalose and sucrose as examples, these substances significantly reduce protein aggregation by enhancing the conformational stability of proteins. In addition, polyols, specific types of amino acids (such as arginine and histidine), polyamine compounds (such as putrescine and spermidine), and peptide dendrimers of basic amino acids also show good protein stabilization effects. Compounds such as high molecular weight polymers, cyclodextrins, RNA aptamers, and EDTA can also be used as protein stabilizers, and they play an important role in protein protection. The present invention successfully avoids the risk of drug degradation caused by incompatible substances by accurately selecting and using suitable freeze-drying excipients, providing a safer and more effective solution for the application of freeze-drying technology.
[0070] The freeze-drying process involved in the present invention comprises three stages executed in sequence: pre-freezing, sublimation drying and analytical drying. In the pre-freezing stage, the present invention adopts a specific method to form a rigid structure of the material to ensure that the subsequent drying process can be carried out stably. It is followed by a primary drying process, namely sublimation drying. In this stage, the free water crystals formed in the pre-freezing process will be directly converted from a solid state to a gas state by sublimation, thereby effectively removing the moisture in the material. In the entire sublimation drying process, the present invention strictly controls the product temperature (i.e., the sublimation interface temperature) to ensure that it is always kept within a range lower than the collapse temperature or eutectic point temperature of the material to prevent the material structure from being damaged. After the sublimation drying is completed, the analytical drying stage is entered, which is also called secondary drying. In this stage, the present invention adopts an analytical method to effectively remove water molecules in the amorphous phase, including adsorbed water and bound water, to further improve the dryness and stability of the product. Through the precise control and synergistic effect of the above three stages, the present invention realizes a stable and efficient freeze-drying treatment of the material, ensuring the stability and safety of the product quality.
[0071] The optimized lyophilized powder of telpotide for injection uses sodium chloride as an osmotic pressure regulator, disodium hydrogen phosphate heptahydrate as a pH buffer, hydrochloric acid and sodium hydroxide as pH regulators, and mannitol as a preferred excipient.
[0072] This application mainly focuses on the dosage form optimization of Eli Lilly's original research telportin injection, so it can be compared with the original prescription, and its information is shown in Table 1.
[0073] Table 1: Eli Lilly Tilpotide Injection Prescription
[0074]
[0075] Unless otherwise specified, the raw materials, reagents, consumables and instruments involved in the present invention are all common commercial products and can be purchased from the market.
[0076] The ultimate vacuum mentioned in this application refers to the maximum vacuum degree that can be achieved by the vacuum pump used. In this application, the ultimate vacuum degree that can be achieved by the vacuum pump used is 30~70 μbar.
[0077] The present invention will be further described below in conjunction with the embodiments.
[0078] Example 1 to Example 10: Study on Preparation Prescription
[0079] The freeze-dried powder preparation process is divided into several steps: liquid preparation, filtration, filling, semi-stoppering, freeze drying, and stoppering and capping. Prepare according to the prescription in Table 2:
[0080] Table 2: Prescriptions of Examples 1 to 10
[0081]
[0082] The specific operations are as follows:
[0083] Preparation to semi-stoppering process: Measure 80% of the prescribed amount of purified water and add it to a beaker, weigh the prescribed amount of excipients, sodium chloride, and sodium dihydrogen phosphate heptahydrate, add them, and stir at room temperature until completely dissolved; add the prescribed amount of raw materials to a beaker, stir to dissolve; adjust the pH to 6-8 with hydrochloric acid and sodium hydroxide, and weigh it; filter with a 0.22 µm filter, fill 1.5 mL into each 6 mL vial, and semi-stopper it.
[0084] Freeze-drying to capping process: The freeze-drying process is: pre-freezing: plate temperature is -40℃, keep warm for 3 hours; primary drying: vacuum degree 300 μbar, plate temperature -25℃, keep warm for 20 hours; secondary drying: plate temperature 20℃, maintain for 10 hours. After the freeze-drying process is completed, nitrogen is filled for protection, plugging, and capping.
[0085] The freeze-dried samples were placed at 40°C and 60°C to examine the stability and compare the quality of the preparations prepared with different prescriptions. They were also compared with the preparations for prefilled needles.
[0086] Method for reconstitution of lyophilized powder: Use a disposable syringe to draw 1.5 mL of water for injection for reconstitution.
[0087] Example 1, Example 2, Example 3, Example 4, Example 7, and Example 8 compare the effects of different excipients on the quality of the preparations.
[0088] Example 4, Example 5 and Example 6 compare the effects of different prescription amounts of mannitol on the quality of the preparation.
[0089] Example 4, Example 9 and Example 10 compare the effects of different prescription amounts of API on the quality of the preparations.
[0090] Example 11 to Example 14: Study on Preparation Process
[0091] The freeze-drying process includes three processes: pre-freezing, primary drying, and secondary drying. Based on the initial freeze-drying process used in the previous prescription screening, the plate temperature, holding time, and vacuum degree are further adjusted. The following four examples show the comparison of different freeze-drying processes. In theory, the pre-freezing temperature should be lower than the glass transition temperature of the product, so the pre-freezing temperature is set to -40°C. The vacuum degree of the primary drying is set to 200 μbar, and the vacuum degree of the secondary drying is the ultimate vacuum.
[0092] The freeze-dried powder preparation process includes the following steps: liquid preparation, filtration, filling, semi-stoppering, freeze drying, stoppering and capping. Prepare according to the prescription in Table 3.
[0093] Table 3: Prescriptions of Examples 11 to 14
[0094]
[0095] The specific operations are as follows:
[0096] Preparation to semi-stoppering process: Measure 80% of the prescribed amount of purified water and add it to a beaker, weigh the prescribed amount of excipients, sodium chloride, and sodium dihydrogen phosphate heptahydrate, add them, and stir at room temperature until completely dissolved; add the prescribed amount of raw materials to a beaker, stir to dissolve; adjust the pH to 6-8 with hydrochloric acid and sodium hydroxide, and weigh it; filter with a 0.22 µm filter, fill 1.5 mL into each 6 mL vial, and semi-stopper it.
[0097] Freeze-drying to capping process: freeze-dry according to the procedure in Table 4. After the freeze-drying process is completed, fill with nitrogen for protection, press the stopper, and cap.
[0098] Table 4: Freeze-drying process of Example 11 to Example 14
[0099]
[0100] The freeze-dried samples were placed at 40°C and 60°C to examine the stability and compare the quality of the preparations prepared with different prescriptions. They were also compared with the preparations for prefilled needles.
[0101] Method for reconstitution of lyophilized powder: Use a disposable syringe to draw 1.5 mL of water for injection for reconstitution.
[0102] Example 11: Prescription information and liquid preparation method are the same as Example 4, and the vacuum degree is increased to 200 μbar. Increasing the vacuum degree helps to accelerate the sublimation process of ice crystals, thereby improving the drying efficiency. In a high vacuum environment, the mean free path of water molecules increases, making it easier for them to sublime directly from a frozen state to a gaseous state, thereby shortening the drying time. Secondly, a high vacuum degree helps to reduce the temperature of the material during the drying process. Since the sublimation process requires the absorption of heat, increasing the vacuum degree can reduce the sublimation temperature and reduce the denaturation or degradation of the material that may occur due to high temperature during the drying process. In addition, a high vacuum degree also helps to maintain the structure and activity of the material. During the freeze-drying process, the material may change due to the movement of water molecules. A high vacuum degree can reduce the influence of gas molecules and reduce the risk of material structure loss, thereby retaining its particle shape, structure and activity.
[0103] Example 12: In order to improve the drying efficiency and ensure that the drug dries quickly while maintaining its structural integrity, the temperature control of the drug is particularly critical. In actual operation, the temperature of the drug should be increased as much as possible, but it must be strictly controlled within a range below its eutectic temperature or collapse temperature to prevent adverse phenomena such as melting, denaturation or structural collapse of the drug. In the sublimation stage, heat is transferred mainly by conduction, while the heat of the freeze-dried product mainly comes from the plate layer in contact with it. It is generally believed in the industry that part of the heat will be taken away during the sublimation process of the product, resulting in a decrease in the product temperature, with a drop of approximately 10 to 15°C. In order to optimize the drying process, this embodiment uses a gradient temperature increase strategy for primary drying and secondary drying, aiming to accelerate the sublimation rate by gradually increasing the temperature, thereby effectively shortening the drying time.
[0104] Example 13 and Example 14: Adding an annealing step. Annealing refers to the process of raising the temperature of the frozen sample to a temperature above the glass transition temperature of the product and below the eutectic temperature, keeping it warm for a period of time, and then lowering the temperature to the freezing temperature. Annealing has many advantages. First, the annealing step helps to strengthen crystallization, promote the complete crystallization of crystalline components and unfrozen water, thereby improving the stability and quality of the drug. Secondly, the annealing step can increase the maximum concentrated liquid glass transition temperature (Tg') of the amorphous phase. By removing the crystalline components with lower Tg' from the amorphous phase, the Tg' of the amorphous phase can be increased, thereby shortening the drying time and improving the drying efficiency. In addition, the annealing step can also change the morphology and size distribution of ice crystals, thereby improving the drying efficiency. The phase behavior and recrystallization during the annealing process can reduce the difference in ice crystal size and the unevenness of the drying rate caused by the difference in nucleation temperature, making the drying of the drug more uniform and efficient. From a kinetic point of view, the annealing process follows the surface energy theory of Gibbs-Curie-Urop, and achieves the equilibrium shape of the crystal by making the unit volume of the crystal have the minimum total surface area free energy, thereby improving the uniformity and stability of the drug. From a thermodynamic point of view, during the annealing process, the viscosity of amorphous materials will decrease as the temperature rises above Tg', resulting in flow and polymerization; while in crystalline materials, small ice crystal molecules will migrate to large ice crystals. This helps to optimize the structure and performance of the drug. Example 13 and Example 14 were annealed at -15°C and -8°C respectively to examine the effects of different annealing temperatures.
[0105] Comparative Example 1: Telpotide Injection (Prefilled Needle)
[0106] The experimental process is divided into several steps: liquid preparation, filtration, filling and stoppering. The preparation is based on the prescription in Table 5.
[0107] Table 5: Prescription of Comparative Example 1
[0108]
[0109] The specific operations are as follows:
[0110] Preparation: Dissolve the prescribed amount of disodium hydrogen phosphate heptahydrate and sodium chloride in water, stir to dissolve, and add water to make up to 70% of the prescribed amount; add the prescribed amount of API to the excipient liquid, stir to dissolve, and add water to make up to 90% of the prescribed amount; adjust the pH to 6.5-7.5 with diluted NaOH or HCl; add an appropriate amount of water for injection to make up to the total weight.
[0111] Filter, fill and stopper: Filter through a 0.22 µm filter, fill 0.5 mL into 1 mL prefilled syringes and stopper.
[0112] Stability test:
[0113] Freeze-dried powder: Prepare samples according to Example 1 to Example 15, take 80 bottles of each, and use high temperature, accelerated and long-term stability tests to examine stability. The high temperature influencing factor experiment was carried out at 60°C, and the key stability inspection items were tested on the 0th day, 5th day and 10th day of the test period. The long-term test was carried out at 40°C, and the key stability inspection items were tested at the end of the 0th month, 3rd month and 6th month of the test period. The long-term test was carried out at 25°C, and the key stability inspection items were tested at the end of 0th month, 3rd month and 6th month.
[0114] The prefilled needles were prepared according to comparative example 1, and 120 samples were taken. The stability was examined by high temperature, accelerated and long-term stability tests. The high temperature influencing factor experiment was carried out at 40°C, and the key stability inspection items were tested on the 0th, 5th and 10th days of the test period. The long-term test was carried out at 25°C, and the key stability inspection items were tested at the end of the 0th, 3rd and 6th months of the test period. The long-term test was carried out at 2-8°C, and the key stability inspection items were tested at the end of 0th, 3rd and 6th months.
[0115] The experimental test data statistics are shown in Table 6-1 and Table 6-2:
[0116] Table 6-1: Stability test results
[0117]
[0118] Table 6-2: Stability test results
[0119]
[0120] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A lyophilized pharmaceutical composition of tepote, characterized in that: The invention comprises 0.15 to 0.25 parts by weight of tepoxetine or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable lyophilization excipient, an osmotic pressure regulator, a buffer and a pH regulator.
2. The lyophilized pharmaceutical composition of telpotide according to claim 1, characterized in that The osmotic pressure regulator is sodium chloride, the buffer is disodium hydrogen phosphate heptahydrate, and the pH regulator is hydrochloric acid or sodium hydroxide; Preferably, the weight portion of the sodium chloride is 0.41 parts, and the weight portion of the disodium hydrogen phosphate heptahydrate is 0.07 parts.
3. The lyophilized pharmaceutical composition of telpotide according to claim 1, characterized in that The lyophilization excipient is at least one of mannitol, lactose, trehalose and sucrose; Preferably, in parts by weight, the lyophilization excipient is: (i) 3 to 8 parts of mannitol; or (ii), 5 parts of lactose; or (iii), 5 parts of trehalose; or (iv) 5 parts of sucrose; or (v), 4 parts of trehalose and 1 part of mannitol; or (vi), 3 parts sucrose and 2 parts mannitol.
4. The freeze-drying process of the freeze-dried pharmaceutical composition of telpotide according to any one of claims 1 to 3, comprising the following steps: Step (1): mixing a lyophilized excipient, an osmotic pressure regulator, and a buffer with water, dissolving them, and then mixing them with telportide, dissolving them, adjusting the pH to 6-8, and filtering to obtain a lyophilized solution; Step (2): freeze-drying the lyophilized solution to obtain a lyophilized preparation of tepoxetine for injection; The freeze-drying comprises three stages: pre-freezing, primary drying and secondary drying; The pre-freezing may or may not include an annealing step; The pre-freezing conditions are: -40°C to -8°C, 3 to 7 hours; The annealing conditions are: -15°C to -8°C, 2 hours; The primary drying conditions are: 200 μbar, -20°C to -10°C, 20 hours; The secondary drying conditions are: extreme vacuum, 10° C. to 20° C., and 8 to 10 hours.
5. The freeze-drying process according to claim 4, characterized in that The osmotic pressure regulator is sodium chloride, and the buffer is disodium hydrogen phosphate heptahydrate; Preferably, the weight portion of the sodium chloride is 0.41 parts, and the weight portion of the disodium hydrogen phosphate heptahydrate is 0.07 parts.
6. The freeze-drying process according to claim 4, characterized in that In parts by weight, the lyophilization excipient is at least one of mannitol, lactose, trehalose, and sucrose; Preferably, in parts by weight, the lyophilization excipient is: (i) 3 to 8 parts of mannitol; or (ii), 5 parts of lactose; or (iii), 5 parts of trehalose; or (iv) 5 parts of sucrose; or (v), 4 parts of trehalose and 1 part of mannitol; or (vi), 3 parts sucrose and 2 parts mannitol.
7. The freeze-drying process according to claim 4, characterized in that The freeze-drying conditions are: Pre-freezing: -40℃, 3 hours; Primary drying: 200 μbar, -20°C, 20 hours; Secondary drying: extreme vacuum, 20°C, 10 hours.
8. The freeze-drying process according to claim 4, characterized in that The freeze-drying conditions are: Pre-freezing: -40℃, 3 hours; Primary drying: 200 μbar, -20°C, 10 hours, then -10°C, 10 hours; Secondary drying: extreme vacuum, 20°C, 5 hours, then 40°C, 3 hours.
9. The freeze-drying process according to claim 4, characterized in that: The freeze-drying conditions are: Pre-freezing: -40℃, 3 hours, then annealing at -15℃ for 2 hours, then -40℃, 2 hours; Primary drying: 200 μbar, -20°C, 10 hours, then -10°C, 10 hours; Secondary drying: extreme vacuum, 20°C, 5 hours, then 40°C, 3 hours.
10. The freeze-drying process according to claim 4, characterized in that The freeze-drying conditions are: Prefreeze: -40℃, 3 hours, then anneal at -8℃ for 2 hours, then -40℃, 2 hours; Primary drying: 200 μbar, -20°C, 10 hours, then -10°C, 10 hours; Secondary drying: extreme vacuum, 20°C, 5 hours, then 40°C, 3 hours.
